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Germline mutations in BRCA1 and BRCA2 confer high risks of breast cancer. However, evidence suggests that these risks are modiﬁed by
other genetic or environmental factors that cluster in families. A recent genome-wide association study has shown that common alleles
at single nucleotide polymorphisms (SNPs) in FGFR2 (rs2981582), TNRC9 (rs3803662), and MAP3K1 (rs889312) are associated with
increased breast cancer risks in the general population. To investigate whether these loci are also associated with breast cancer risk in
BRCA1 and BRCA2mutation carriers, we genotyped these SNPs in a sample of 10,358mutation carriers from 23 studies. Theminor alleles
of SNP rs2981582 and rs889312 were each associated with increased breast cancer risk in BRCA2mutation carriers (per-allele hazard ratio
[HR] ¼ 1.32, 95% CI: 1.20–1.45, ptrend ¼ 1.7 3 108 and HR ¼ 1.12, 95% CI: 1.02–1.24, ptrend ¼ 0.02) but not in BRCA1 carriers.
rs3803662 was associated with increased breast cancer risk in both BRCA1 and BRCA2 mutation carriers (per-allele HR ¼ 1.13, 95%
CI: 1.06–1.20, ptrend ¼ 5 3 105 in BRCA1 and BRCA2 combined). These loci appear to interact multiplicatively on breast cancer risk
in BRCA2 mutation carriers. The differences in the effects of the FGFR2 and MAP3K1 SNPs between BRCA1 and BRCA2 carriers point
to differences in the biology of BRCA1 and BRCA2 breast cancer tumors and conﬁrm the distinct nature of breast cancer in BRCA1
mutation carriers.Introduction
BRCA1 (MIM 113705) and BRCA2 (MIM 600185) muta-
tions confer high risks of breast and other cancers. A
meta-analysis of mutation-positive families identiﬁed
through population-based studies of breast or ovarian
cancer estimated the risk of breast cancer by age 70
years to be 65% and 45% for BRCA1 and BRCA2 muta-
tion carriers, respectively.1 Although the pattern of risk
was similar, the absolute magnitude of risk in that study
was lower than in previously published studies based on
families with multiple affected individuals, in particular
for BRCA2 mutation carriers.2 The breast cancer risks
in BRCA1 and BRCA2 mutation carriers have also been
found to vary by the age at diagnosis and the type of
cancer (unilateral breast cancer, contralateral breast
cancer, or ovarian cancer) in the index patient.1,3,4
Such observations are consistent with the hypothesis
that breast cancer risks in BRCA1 and BRCA2 mutation
carriers are modiﬁed by other genetic or environmental
factors that cluster in families.1,3 Further evidence of
genetic modiﬁers of risk comes from segregation-analysis
models that have quantiﬁed the extent of variability in
the risk of breast cancer in mutation carriers in terms of
a polygenic-modifying variance5,6. In addition, Begg
et al.3 demonstrated signiﬁcant between-family variation
in risk.
A number of studies have evaluated associations be-
tween genetic variants and breast cancer risk in BRCA1
and BRCA2 mutation carriers7,8, but apart from a recent
CIMBA (Consortium of Investigators of Modiﬁers of
BRCA1/2) study that found evidence of association among
BRCA2 mutation carriers who are rare homozygotes for
a single nucleotide polymorphism (SNP) in RAD51, no
other such associations have been reliably identiﬁed.9 A
recent genome-wide association study in breast cancer
identiﬁed ﬁve common susceptibility alleles that are asso-
ciated with an increased risk of breast cancer in the general
population.10 To address whether these polymorphisms
are also associated with the risk of breast cancer in
BRCA1 and BRCA2 mutation carriers, we typed the three
SNPs with the strongest evidence of association in BRCA1
and BRCA2 mutation carriers from the CIMBA study.7938 The American Journal of Human Genetics 82, 937–948, April 20Material and Methods
Study Sample
Eligibility was restricted to female carriers who had pathogenic
mutations in BRCA1 or BRCA2 and were 18 years old or older.
Twenty-three different studies submitted information on muta-
tion carriers (Table 1). Information collected included the year of
birth; mutation description, including nucleotide position and
base change; age at last follow-up; ages at breast and ovarian can-
cer diagnosis; and age or date at bilateral prophylactic mastec-
tomy. Information was also available on the country of residence,
which was deﬁned to be the country of the clinic at which the
carriers were recruited (some studies included carriers from several
countries). Related individuals were identiﬁed through a unique
family identiﬁer. Women were included in the analysis if they
carried mutations that were pathogenic according to generally
recognized criteria9 (Breast Cancer Information Core, BIC). All
carriers participated in clinical and research studies at the host
institutions under IRB-approved protocols. Further details of the
CIMBA initiative can be found elsewhere.7
Genotyping
All centers included at least 2% of the samples in duplicate, no tem-
plate controls in every plate, and a random mixture of affected and
unaffectedcarriers. Samples that failed intwoormoreof theSNPsgen-
otypedwere excluded from the analysis. A study was included in the
analysis only if the call rate was over 95% after samples that failed at
multiple SNPs had been excluded. The concordance between dupli-
cates had to be at least 98%. To further validate the accuracy of geno-
typingacrosscenters,we requiredallgroups togenotype95DNAsam-
ples froma standard test plate for all three SNPs. If thegenotypingwas
inconsistent formore thanone sample in the test plate, the studywas
excluded from the analysis of that SNP. Based on these criteria, four
studies were excluded from the analysis of rs2981582, and three
studies were excluded from the analysis of rs3803662. As an extra
genotyping quality-control check, we also evaluated deviation from
Hardy-Weinberg equilibrium (HWE) among unrelated subjects
separately for each SNP and study. Two studies gave HWE p values
of 0.02 and 0.001. Examination of the cluster plots for these SNPs
did not reveal any unusual patterns, and these studies were therefore
included in the analysis. The genotype frequencies among unrelated
individuals for all other studies and SNPs were consistent with HWE.
Statistical Analysis
After the above exclusions, a total of 10,358 unique BRCA1 and
BRCA2 mutation carriers had an observed genotype for at least08
Table 1. Number of BRCA1 and BRCA2 Mutation Carriers by Study
Study Countrya BRCA1 BRCA2 BRCA1 and BRCA2 Genotyping platform
EMBRACE U.K. and Eire 658 471 3 iPLEXb
Spanish National Cancer
Centre (CNIO)
Spain 167 205 0 Taqman
Deutsches
Krebsforschungszentrum
(DKFZ)
Germany 122 50 0 Taqman, MALDI-TOF MS,
Biplex
Fox Chase Cancer Center
(FCCC)
U.S.A. 50 41 1 iPLEXb
Genetic Modifiers of
cancer risk in BRCA1/2
mutation carriers (GEMO)
France 1102 554 0 Taqman
German Consortium of
Hereditary Breast and
Ovarian Cancer (GC-HBOC)
Germany 568 280 3 BIORAD iCycler
Hospital Clinico San Carlos
(HCSC)
Spain 90 78 0 Taqman
Helsinki Breast Cancer
Study (HBCS)
Finland 102 104 0 Taqman
Interdisciplinary Health
Research International
Team Breast Cancer
Susceptibility (INHERIT
BRCAs)
Quebec-Canada 72 82 0 Taqman
kConFab Australia 426 353 0 iPLEXb
Modifiers and Genetics in
Cancer (MAGIC)
U.S.A. 683 378 1 Taqman
MAYO U.S.A. 108 54 0 Taqman
Milan Breast Cancer Study
Group (MBCSG)
Italy 251 135 0 Taqman
National Cancer Institute
(NCI)
U.S.A. 147 50 0 Taqman
National Israeli Cancer
Control Center (NICCC)
Israel 283 160 1 Taqman
Ontario Cancer Genetics
Network (OCGN)
Canada 195 143 0 Taqman
Odense University
Hospital(OUH)
Denmark 106 0 0 Taqman
Pisa Breast Cancer Study
(PBCS)
Italy 54 30 0 iPLEXb
Sheeba Medical Centre
(SMC)-Tel Hashomer
Israel 283 101 0 Taqman
SWE-BRCA Sweden 426 127 0 iPLEXb
Mod-SQuaD Czech Republic 138 37 0
University of
Pennsylvania (UPENN)
U.S.A. 271 124 1 iPLEXb
HEriditary Breast and
Ovarian study Netherlands
(DNA-HEBON)
The Netherlands 489 0 0 iPLEXb
Total 6791 3557 10
a Coordinating center.
b Indicates that samples were genotyped at a central location (Queensland Institute of Medical Research).one of the three polymorphisms (6,791 BRCA1 carriers; 3,557
BRCA2 carriers; and ten BRCA1 and BRCA2 carriers; Table 1).
Individuals were classiﬁed according to their age at diagnosis of
breast cancer or their age at last follow-up. For this purpose, indi-
viduals were censored at the age of the ﬁrst breast cancer diagnosis
(n ¼ 5,489), ovarian cancer diagnosis (n ¼ 975), or bilateral
prophylactic mastectomy (n ¼ 340) or the age at last observation
(n ¼ 3,554). Only individuals censored at breast cancer diagnosis
were assumed to be affected (Table 2). Mutation carriers were cen-
sored at ovarian cancer diagnosis and were considered unaffected.TheWe ignored data on breast cancer occurrence after an ovarian
cancer because the risk of breast cancer may be affected by the
treatment for ovarian cancer, and the recording of a second breast
cancer may be inaccurate in a woman with advanced ovarian
cancer.
We performed additional sensitivity analyses to investigate
whether any bias could be introduced in our results as a result of
our assumptions. If the SNPs under study were associated with
disease survival in carriers, the estimated HRs might be affected
by the inclusion of prevalent cases. We therefore performedAmerican Journal of Human Genetics 82, 937–948, April 2008 939
Table 2. Patient Characteristics
BRCA1a BRCA2
Characteristic Total Unaffected Breast Cancer Unaffected Breast Cancer
Number 10,358 3300 3501 1574 1983
Person-years follow-up 440,252 140,541 14,2734 69,778 87,199
Median age at censure (IQR) 41 (34–49) 41 (33–50) 40 (34–46) 43 (34–52) 43 (37–50)
Age at Censure, N (%)
<30 1222 (10.8) 499 (15.1) 320 (9.1) 196 (12.5) 107 (5.4)
30–39 3436 (33.2) 958 (29.0) 1416 (40.5) 443 (28.1) 619 (31.2)
40–49 3305 (31.9) 946 (28.7) 1200 (12.1) 428 (27.2) 731 (36.9)
50–59 1683 (16.3) 584 (17.7) 423 (12.1) 295 (18.7) 381 (19.2)
60–69 562 (5.4) 208 (6.3) 109 (3.1) 135 (8.6) 110 (5.5)
70þ 250 (2.4) 105 (3.2) 33 (0.9) 77 (4.9) 35 (1.8)
Year of Birth, N (%)
<1920 92 (0.9) 25 (0.8) 32 (0.9) 20 (1.3) 15 (0.8)
1920–1929 383 (3.7) 93 (2.8) 140 (4.0) 48 (3.0) 102 (5.1)
1930–1939 963 (9.3) 246 (7.4) 335 (9.6) 138 (8.8) 244 (12.3)
1940–1949 2066 (20.0) 511 (15.5) 836 (23.9) 228 (14.5) 491 (24.8)
1950–1959 2913 (28.1) 804 (24.4) 1,122 (32.0) 368 (23.4) 619 (31.2)
1960þ 3741 (38.0) 1,621 (49.1) 1,036 (29.6) 772 (49.0) 512 (25.8)
Risk-Reducing Salpingo-Oophorectomy (RRSO)
No RRSO 6613 (63.8) 2,032 (61.6) 2369 (67.7) 928 (59.0) 1284 (64.7)
RRSO 577 (5.6) 318 (9.6) 85 (2.4) 119 (7.6) 55 (2.8)
Missing 3168 (30.6) 950 (28.8) 1047 (29.9) 527 (33.4) 644 (32.5)
IQR: Interquartile range.
a Includes the ten females who have mutations in both BRCA1 and BRCA2.analyses after excluding cases diagnosedmore than 5 years prior to
the age at last follow-up. Risk-reducing salpingo-oophorectomy
(RRSO) reduces the risk of breast cancer in BRCA1 and BRCA2
mutation carriers.11,12 To investigate whether allowance for
RRSO alters our results in any way, we repeated the analysis after
censoring the BRCA1 and BRCA2 mutation carriers at the time of
surgery. In addition, because carriers diagnosed with ovarian can-
cer were treated as unaffected at the age of diagnosis, if any of
these SNPs are associated with ovarian cancer risk, the hazard ratio
(HR) estimates might be underestimated or overestimated depend-
ing on the direction of the association. Although there is no
evidence of such an association between these SNPs and ovarian
cancer in the general population (Song et al., American Society
of Human Genetics meeting 2007, San Diego, USA, Abstract
428), we examined the sensitivity of our results to this assumption
by excluding mutation carriers who were censored at a ﬁrst
ovarian cancer.
Our analyses are complicated by the fact that BRCA1 and BRCA2
mutation carriers are not randomly sampled with respect to their
disease status. Many carriers are sampled through families seen
in genetic clinics. The ﬁrst tested individual in a family is usually
someone diagnosed with cancer at a relatively young age. Such
study designs therefore tend to lead to an oversampling of affected
individuals, and standard analytical methods such as Cox regres-
sion might lead to biased estimates of the risk ratios.13 For exam-
ple, consider an individual affected at age t. In a standard analysis
of a cohort study, the SNP genotype for the individual will be com-
pared with those of all individuals at risk at age t. This analysis
leads to consistent estimates of the HR estimates. However, in
the present design, mutation carriers are already selected on the
basis of disease status (where affected individuals are over-940 The American Journal of Human Genetics 82, 937–948, April 20sampled). If standard cohort analysis were applied to these data,
it would cause affected individuals at age t to be compared to
unaffected carriers selected on the basis of their future disease
status. If the genotype is associated with the disease, the risk
estimate will be biased to zero because too many affected individ-
uals (in whom the at-risk genotype is overrepresented) are
included in the comparison group. Simulation studies have shown
that this effect can be quite marked.13
To correct for this potential bias, we analyzed the data within
a survival analysis framework bymodelling the retrospective likeli-
hood of the observed genotypes conditional on the disease pheno-
types. A detailed description of the retrospective-likelihood
approach has been published.9 The effect of each SNP was mod-
eled either as a per-allele HR or as separate HRs for heterozygotes
and homozygotes. The HRs were assumed to be independent of
age (i.e., we used a Cox proportional-hazards model). We veriﬁed
the assumption of proportional hazards by examining the Ka-
plan-Meier estimates of the survival functions by genotype and
by subsequently adding a genotype 3 age interaction term to
the model in order to ﬁt models in which the HR changed with
age. Analyses were carried out with the pedigree-analysis software
MENDEL.14 Under this approach, the baseline age-speciﬁc inci-
dence rates in the Cox proportional-hazards model are chosen
such that the overall breast cancer incidence rates, averaged over
all genotypic categories, agree with external estimates of BRCA1
and BRCA2 incidence rates.6 We examined between-study hetero-
geneity by comparing the models that allowed for study-speciﬁc
log-hazard ratios against models in which the same log-hazard
ratio was assumed to apply to all studies. All analyses were strati-
ﬁed by study group and country of residence (where numbers
were sufﬁciently large) and used calendar-year- and cohort-speciﬁc08
breast cancer incidence rates for BRCA1 and BRCA2.6 The risk of
breast cancer in compound BRCA1 and BRCA2 mutation carriers
was assumed to be that for BRCA1 mutation carriers. We used a
robust variance-estimation approach to allow for the nonindepen-
dence among related carriers.15,16 To evaluate the combined
effects of the signiﬁcant SNPs on breast cancer risk, we ﬁtted amul-
tiplicative (log-additive) model that included a parameter for the
per-allele log-hazard ratio for each of the SNPs and compared
this to a fully saturated model in which a separate parameter
was ﬁtted for each multi-locus genotype. The proportions of the
modifying variance explained by the FGFR2, TNCR9, and
MAP3K1 SNPs were estimated by ln(c)/s2, where c is the estimated
coefﬁcient of variation in incidence rates due to each SNP17,18 and
s2 is the estimated modifying variance (1.32 and 1.73 for BRCA1
and BRCA2, respectively6). We estimated the total proportion of
the modifying variance due to all SNPs by adding the individual
proportions, i.e., by assuming that the loci combined multiplica-
tively. In the text, the term ‘‘signiﬁcant’’ is taken to mean a signif-
icance level of 5%.
Results
Results are shown in Table 3. SNP rs2981582 in FGFR2 was
associated with breast cancer risk in the combined sample
of BRCA1 and BRCA2 mutation carriers (ptrend ¼ 0.0001).
However, when BRCA1 and BRCA2 carriers were analyzed
separately, the association was restricted to BRCA2 muta-
tion carriers (ptrend ¼ 23 108), and there was no evidence
of an association among BRCA1 carriers (ptrend ¼ 0.6;
p ¼ 1.3 3 105 for the difference in the estimates between
BRCA1 and BRCA2 carriers). The estimated effect among
BRCA2mutation carriers was consistent with a multiplica-
tive model in which each copy of the disease allele
conferred a hazard ratio (HR) of 1.32 (95%CI: 1.20–1.45)
(Figure 1). There was some suggestion that the HRs might
differ between studies for BRCA1 (p ¼ 0.03), but there
was no evidence of heterogeneity for BRCA2 (p ¼ 0.11).
TNRC9 SNP rs3803662 was associated with an increased
risk of breast cancer in both BRCA1 and BRCA2 mutation
carriers (ptrend ¼ 0.004 and 0.009, respectively; joint
ptrend ¼ 0.00005). The per-allele HR was estimated to be
1.11 (95%CI: 1.03–1.19) for BRCA1 carriers and 1.15
(95%CI: 1.03–1.27) for BRCA2 carriers (p ¼ 0.6 for the dif-
ference in the BRCA1 and BRCA2 per-allele HR estimates).
There was no evidence of heterogeneity in the HRs among
studies (BRCA1: p ¼ 0.67; BRCA2: p ¼ 0.63, Figure 2).
There was no evidence that SNP rs889312 in MAP3K1
was associated with breast cancer risk in the combined
sample of BRCA1 and BRCA2 mutation carriers or in
BRCA1 carriers alone (ptrend ¼ 0.29 and 0.86, respectively).
However, BRCA2 mutation carriers who carried a copy of
the minor allele of this SNP were at increased risk of breast
cancer (per-allele HR ¼ 1.12, 95% CI: 1.02–1.24, ptrend ¼
0.02). There was some evidence of heterogeneity in the
HRs between studies for BRCA2 (p ¼ 0.02) but not for
BRCA1 (p ¼ 0.06) mutation carriers (Figure 3). We also
investigated whether the HRs change with age by includ-
ing an age 3 genotype interaction term in the model.TheThere was no signiﬁcant evidence that HRs vary by age
for any of the variants.
If these SNPs were associated with disease survival in
carriers, the estimated HRs might be affected by the inclu-
sion of prevalent cancer cases. We therefore repeated our
analysis after excluding cancer cases diagnosed more
than ﬁve years prior to their study recruitment. A total of
7,027 BRCA1 and BRCA2 mutation carriers were eligible
for this analysis (2,523 affected; 4,504 unaffected). The
estimated per-allele HRs among BRCA2 mutation carriers
were virtually unchanged for the FGFR2 SNP rs2981582
(per-allele HR 1.37 (95%CI: 1.22–1.54; ptrend ¼ 2 3 107)
and the MAP3K1 SNP rs889312 (HR: 1.11, 95%CI: 0.98–
1.25, ptrend ¼ 0.11), but slightly higher for the TNRC9
SNP rs3803662 (BRCA1: 1.17 (95% CI:1.06-1.28, ptrend ¼
0.001; BRCA2: 1.24 (95%CI: 1.10–1.41, ptrend ¼ 0.0008;
BRCA1and BRCA2 combined ptrend ¼ 9 3 107).
Risk-reducing salpingo-oophorectomy (RRSO) reduces
the risk of breast cancer in BRCA1 and BRCA2mutation car-
riers.11,12 To investigate whether allowance for RRSO alters
our results in anyway,we repeated the analysis after censor-
ing the BRCA1 and BRCA2mutation carriers at the time of
surgery. Because information on RRSO was missing for
approximately 30% of the carriers, we performed this anal-
ysis by ﬁrst including all carriers in the analysis and
assuming that carriers with no RRSO information did not
have the surgery; we then repeated the analysis after
including only carriers with data on RRSO as previously
described.9 When all BRCA1 and BRCA2 mutation carriers
were included in this analysis, the HRs and signiﬁcance
test results were very similar to results of the analysis in
which no censoring at RRSO took place (Table S1 in the
Supplemental Data). When carriers with no information
on RRSO were excluded, the sample size was reduced from
10,358 to 7,190. The estimated HRs remained virtually
identical to those in the primary analysis, although the
p values were increased, because of a reduced sample size
(Table S1; rs2981582 in BRCA2: ptrend ¼ 6 3 106;
rs3803662 in BRCA1, BRCA2 and combined: ptrend ¼ 0.03,
0 .02, 0.001 respectively; rs889312 inBRCA2: ptrend¼ 0.16).
BRCA1 and BRCA2 mutations are also associated with
increased risks of ovarian cancer.1 Carriers who had devel-
oped ovarian cancer were included in our analyses as unaf-
fected. A possible bias could have been introduced if these
SNPs were associated with ovarian cancer risk. Although
there is no evidence of such an association in the general
population (American Society of Human Genetics meeting
2007, San Diego, USA, Abstract 428), we repeated our
analyses by excluding the 975 mutation carriers who
were censored at an ovarian cancer diagnosis. The esti-
mated HRs were unchanged (Table S2).
To evaluate the potential combined effects of the two
most signiﬁcant SNPs on breast cancer risk in BRCA2
mutation carriers, we ﬁtted a multiplicative model (log
additive, 2 degrees of freedom [df]) for the effects of the
FGFR2 SNP rs2981582 and TNRC9 SNP rs3803662 and
compared this against a fully saturated model in whichAmerican Journal of Human Genetics 82, 937–948, April 2008 941
Table 3. Genotype Frequencies by Mutation and Disease Status and Hazard-Ratio Estimates
Unaffected (%) Affected (%) HRa 95% CI p Value
FGFR2 rs2981582
BRCA1 and BRCA2 GG 1547 (36.0) 1647 (33.0) 1.00
GA 2051 (47.7) 2407 (48.2) 1.10 1.01–1.20
AA 703 (16.3) 936 (18.8) 1.24 1.11–1.38
2-df test 0.00045
Per allele 1.11 1.05–1.17 0.000095
BRCA1 GG 1021 (35.5) 1114 (35.3) 1.00
GA 1376 (47.9) 1487 (47.2) 0.99 0.89–1.10
AA 477 (16.6) 553 (17.5) 1.05 0.92–1.20
2-df test 0.65
Per allele 1.02 0.95–1.09 0.60
BRCA2 GG 526 (36.9) 533 (29.0) 1.00
GA 675 (47.3) 920 (50.1) 1.35 1.17–1.57
AA 226 (15.8) 383 (20.9) 1.72 1.41–2.09
2-df test 9.9 3 108
Per allele 1.32 1.20–1.45 1.7 3 108
TNRC9 rs3803662
BRCA1 and BRCA2 CC 2244 (50.3) 2422 (47.6) 1.00
CT 1831 (41.1) 2173 (42.7) 1.13 1.04–1.22
TT 382 (8.6) 497 (9.7) 1.28 1.11–1.46
2-df test 0.00027
Per allele 1.13 1.06–1.20 5 3 105
BRCA1 CC 1542 (50.9) 1571 (48.2) 1.00
CT 1238 (40.8) 1384 (42.4) 1.11 1.01–1.22
TT 251 (8.3) 308 (9.4) 1.24 1.04–1.46
2-df test 0.017
Per allele 1.11 1.03–1.19 0.0043
BRCA2 CC 702 (49.2) 851 (46.5) 1.00
CT 593 (41.6) 789 (43.2) 1.15 1.00–1.32
TT 131 (9.2) 189 (10.3) 1.32 1.04-1.67
2-df test 0.033
Per allele 1.15 1.03–1.27 0.009
MAP3K1 rs889312
BRCA1 and BRCA2 AA 2440 (50.5) 2711 (49.9) 1.00
AC 1963 (40.7) 2195 (40.4) 1.02 0.94–1.10
CC 426 (8.8) 530 (9.8) 1.08 0.95–1.22
2-df test 0.53
Per allele 1.03 0.97–1.09 0.29
BRCA1 AA 1637 (50.0) 1743 (50.2) 1.00
AC 1329 (40.6) 1394 (40.2) 1.00 0.91–1.09
CC 306 (9.4) 332 (9.6) 0.98 0.84–1.15
2-df test 0.98
Per allele 0.99 0.93–1.06 0.86
BRCA2 AA 803 (51.6) 968 (49.2) 1.00
AC 634 (40.7) 801 (40.7) 1.08 0.94–1.24
CC 120 (7.7) 198 (10.1) 1.32 1.05–1.66
2-df test 0.049
Per allele 1.12 1.02–1.24 0.020
a In all cases, where significant, the effect is consistent with a multiplicative model in which each copy of the disease allele confers the estimated,
per-allele HR.a separate parameter was ﬁtted for each FGFR2-TNRC9
combined genotype (8 df). The HR estimates for all nine
genotypes under the multiplicative and fully saturated
models are shown in Table 4. The HRs were remarkably
similar under the two models, and there was no signiﬁcant
evidence that the fully saturated model ﬁt better than the
multiplicative model (c2 ¼ 4.48, df ¼ 6, p-value:0.61).942 The American Journal of Human Genetics 82, 937–948, April 20Under the multiplicative model, the highest HR was 2.26
for carriers who were homozygotes for the risk allele at
both loci in comparison to BRCA2 carriers who did not
have any risk alleles. Based on the minor allele frequencies
of the FGFR2 and TNRC9 SNPs in the general population,10
approximately 36% of the BRCA2 mutation carriers will
have HRs in excess of 1.5 in comparison to the 20% of08
carriers who will have no copies of the disease allele at
either FGFR2 or TNRC9.
Discussion
Our results provide strong evidence that SNP rs2981582 in
FGFR2 is associated with breast cancer risk in BRCA2
mutation carriers and that SNP rs3803662 in TNRC9 is as-
sociated with breast cancer risk in both BRCA1 and BRCA2
mutation carriers. With our sample size, we can rule out
a comparable involvement of rs2981582 in the breast
cancer risk for BRCA1 mutation carriers. These results
Figure 1. Study-Specific Estimates of
the Per-Allele Hazard Ratio for SNP
rs2981582 in FGFR2
The area of the square is proportional to
the inverse of the variance of the estimate.
Horizontal lines represent the 95% confi-
dence intervals.
Figure 2. Study-Specific Estimates of
the Per-Allele Hazard Ratio for SNP
rs3803662 in TNRC9
The area of the square is proportional to
the inverse of the variance of the estimate.
Horizontal lines represent the 95% confi-
dence intervals.
were unaltered when we accounted
for survival bias and risk-reducing
salpingo-oophorectomy or when we
included ovarian cancer cases as unaf-
fected in the analysis. There was no
evidence of heterogeneity in the HRs
between studies. The evidence of
association with SNP rs889312 in
MAP3K1 was weaker and was re-
stricted to BRCA2 mutation carriers.
For all three SNPs, the estimated HRs
in BRCA2 carriers were very similar
to the corresponding estimated odds
ratios (OR) for breast cancer derived from data from large
population-based case-control studies10 (per-allele ORs:
1.26, 1.20 and 1.13 for rs2981582 [FGFR2], rs3803662
[TNRC9], and rs889312 [MAP3K1], respectively). Based
on the per-allele HR estimates, the frequencies of the risk
alleles in the general population10 and recent estimates
of the genetic variance of the breast cancer risks in
BRCA1 and BRCA2 mutation carriers (‘‘modifying vari-
ance’’) derived from breast cancer segregation analyses6,
the TNRC9 SNP is predicted to account for approximately
0.5% of the BRCA1 modifying variance. The SNPs in
FGFR2, TNRC9, and MAP3K1 are estimated to account for
2.8% of the BRCA2 modifying variance.The American Journal of Human Genetics 82, 937–948, April 2008 943
It has been reported thatmore than 90% of BRCA1 breast
cancer tumors are estrogen receptor (ER) negative, whereas
BRCA2 breast cancer tumors have an ERdistribution similar
to that in the general population, in which themajority are
ER positive.19 A recent Breast Cancer Association Consor-
tium study found that the FGFR2 SNP rs2981582 was
more strongly associated with ER-positive breast cancers
than ER-negative tumors (OR: 1.31 versus 1.08, respec-
tively).20 The same study found that the TNRC9 SNP
rs3803662 was associated with the risk of both ER-positive
and ER-negative breast cancers, which is again consistent
with our results. Therefore, our results are consistent with
the hypothesis that the SNPs modify the risk of breast can-
cer to a similar, relative extent in carriers for eitherBRCA2or
(in the case of TNRC9 rs3803662) BRCA1 and noncarriers.
Table 4. HR Estimates for the Combined Genotypes of SNPs
in FGFR2 and TNRC9 among BRCA2 Carriers under
a Multiplicative Model and under a Fully Saturated Model
FGFR2/TNRC9
Genotype
HR
Multiplicative
Modela
HR Fully
Saturated
Model
Predicted Genotype
Distributionb (%)
GG/CC 1.00 1.00 20.4
GG/CT 1.16 1.05 14.3
GG/TT 1.35 1.23 2.5
GA/CC 1.29 1.25 26.1
GA/CT 1.50 1.44 18.3
GA/TT 1.75 1.72 3.2
AA/CC 1.67 1.41 8.3
AA/CT 1.94 2.08 5.9
AA/TT 2.26 2.08 1.0
a Multiplicative model, per-allele HRs. FGFR2: 1.29 (95%CI: 1.17–1.43);
TNRC9: 1.16 (95%CI: 1.04–1.30).
b Assuming a minor allele frequency of 0.39 for FGFR2 (rs rs2981582) and
0.26 for TNRC9 (rs rs3803662).10
Figure 3. Study-Specific Estimates of
the Per-Allele Hazard Ratio for SNP
rs889312 in MAP3K1
The area of the square is proportional to the
inverse of the variance of the estimate. Hor-
izontal lines represent the 95% confidence
intervals.
The weaker (or null) effect in BRCA1
carriers for the FGFR2 SNP rs2981582
is explicable by its weak effect on ER
negative disease and is further conﬁr-
mation of the distinct nature of breast
cancer in BRCA1mutation carriers.
One potential limitation of this
study is that it was not possible to
take the precise family histories of car-
riers into account because CIMBA
does not currently collect this infor-
mation. Although this does not inval-
idate the statistical tests of association,
we could not therefore assess directly
how the breast cancer risk in carriers associated with these
SNPs varies by the degree of family history. Such effects
might be important in the context of genetic counseling.
Another limitation is that we did not have detailed tumor
characteristics such as ER status available for our carriers.
For example, it might be that the FGFR2 SNP is associated
with the risk of ER-positive breast cancer in BRCA1 carriers,
but this is not observable in our dataset because they only
account for a small fraction of cases. In addition, informa-
tion on whether any of the mutation carriers were on
chemoprevention was also not available. However, chemo-
prevention is not expected to be a confounder in our anal-
yses because its use is unlikely to be associated with the
SNPs under investigation. A ﬁnal uncertainty is that the
SNPs we have tested are probably not the variants causally
related to the disease, but are correlated with them. This
does not invalidate the associations, but it might mean
that the associations with the causal variants, when they
are identiﬁed, will prove to be somewhat stronger.
Because BRCA1 and BRCA2 mutations confer high risks,
the modest HRs associated with these SNPs translate into
marked differences in absolute risk between extreme geno-
types. For example, the absolute risk of breast cancer by age
70 among BRCA2 mutation carriers is predicted to be 43%
for common homozygotes at the FGFR2 locus and 63% for
rare homozygotes. The corresponding risks for TNRC9 are
48% and 58% for common and rare homozygotes, respec-
tively. However, when the combined effects of the two loci
are considered, the absolute risk varies from 41% (for car-
riers with no risk alleles) to 70% (for carriers with four
risk alleles; see Figure 4). Although only 1% of carriers are
doubly homozygous, approximately 36% of carriers will
have a HR of 1.5 or greater in comparison to the 20% of car-
riers with no risk alleles. This corresponds to an absolute944 The American Journal of Human Genetics 82, 937–948, April 2008
Figure 4. Cumulative Risk of Breast Cancer among BRCA2 Mutation Carriers by Combined FGFR2 and TNRC9 Genotype under a
Multiplicative Model for the Joint Effects of the Loci
The combined FGFR2 and TNRC9 genotypes are as follows: FGFR2 ¼ GG, GA, or AA; TNRC9 ¼ CC, CT, or TT. ‘‘Average’’ represents the
cumulative breast cancer risk over all possible modifying effects among BRCA2 mutation carriers born after 1950. The minor allele
frequencies for the FGFR2 and TNRC9 SNPs were assumed to be 0.39 and 0.26, respectively.risk of 55% or greater by age 70. If further such risk alleles
are identiﬁed (for example, through additional genome
scans), the proportion of carriers for whom the risk can
be modiﬁed substantially will increase. These risks might
also be affected by other factors, including family history,
mutation type, and lifestyle risk factors, and future studies
should aim to investigate these effects.
Supplemental Data
Two additional tables are available online at http://www.ajhg.org/.
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